Effects of atorvastatin on PDCD4/NF-κB/TNF-α signaling pathway during coronary microembolization of miniature pigs.

[1]  Lang Li,et al.  Mechanism of programmed cell death factor 4/nuclear factor-κB signaling pathway in porcine coronary micro-embolization-induced cardiac dysfunction , 2015, Experimental biology and medicine.

[2]  Lang Li,et al.  Induction of Myocardial PDCD4 in Coronary Microembolization-Related Cardiac Dysfunction: Evidence from a Large-Animal Study , 2014, Cellular Physiology and Biochemistry.

[3]  Lang Li,et al.  The Involvement of Phosphatase and Tensin Homolog Deleted on Chromosome Ten (PTEN) in the Regulation of Inflammation Following Coronary Microembolization , 2014, Cellular Physiology and Biochemistry.

[4]  Lang Li,et al.  Effect of Intensive Atorvastatin Therapy on Periprocedural PDCD4 Expression in CD4+ T Lymphocytes of Patients with Unstable Angina Undergoing Percutaneous Coronary Intervention , 2014, Cardiology.

[5]  Jun Liu,et al.  Association between cholesterol synthesis/absorption markers and effects of cholesterol lowering by atorvastatin among patients with high risk of coronary heart disease[S] , 2013, Journal of Lipid Research.

[6]  S. Adams,et al.  Lipid lowering efficacy of atorvastatin. , 2012, The Cochrane database of systematic reviews.

[7]  Lang Li,et al.  Effect of Atorvastatin (Lipitor) on Myocardial Apoptosis and Caspase-8 Activation Following Coronary Microembolization , 2011, Cell Biochemistry and Biophysics.

[8]  Lang Li,et al.  The Role of ERK1/2 Signaling Pathway in Coronary Microembolization-Induced Rat Myocardial Inflammation and Injury , 2010, Cardiology.

[9]  Raimund Erbel,et al.  Impact of atherosclerotic plaque composition on coronary microembolization during percutaneous coronary interventions , 2008, Basic Research in Cardiology.

[10]  R. Jaffe,et al.  Microvascular Obstruction and the No-Reflow Phenomenon After Percutaneous Coronary Intervention , 2008, Circulation.

[11]  V. Pasceri,et al.  Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. , 2007, Journal of the American College of Cardiology.

[12]  V. Pasceri,et al.  Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: results from the ARMYDA-CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy. , 2006, Journal of the American College of Cardiology.

[13]  K. Mensah,et al.  Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: a potential role for phosphatase and tensin homolog deleted on chromosome ten? , 2005, Journal of the American College of Cardiology.

[14]  V. Pasceri,et al.  Randomized Trial of Atorvastatin for Reduction of Myocardial Damage During Coronary Intervention: Results From the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) Study , 2004, Circulation.

[15]  R. Kloner,et al.  Microvascular Alterations After Temporary Coronary Artery Occlusion: The No-Reflow Phenomenon , 2004, Journal of cardiovascular pharmacology and therapeutics.

[16]  G. Heusch,et al.  Myocardial Dysfunction With Coronary Microembolization: Signal Transduction Through a Sequence of Nitric Oxide, Tumor Necrosis Factor-&agr;, and Sphingosine , 2002, Circulation research.

[17]  Lang Li,et al.  Effect of metoprolol on myocardial apoptosis and caspase-9 activation after coronary microembolization in rats. , 2013, Experimental and clinical cardiology.